Exome Sequencing Reveals Diagnosis of LAMA2-Muscular Dystrophy and Possibility of Coexisting Bethlem Myopathy in a Neonate

Abstract

We reported a neonate presenting with muscle weakness, hypotonia, and joint contractures since birth. Investigations revealed significantly elevated creatinine-phosphokinase, abnormal electromyography suggestive of muscle disease and normal magnetic resonance imaging (MRI) of the brain. Exome sequencing revealed homozygous pathogenic mutations in LAMA2 (NM_000426.3: c.7881T > G, p.(His2627Gln)) and a heterozygous likely-pathogenic mutation in COL6A2 (NM_001849.3: c.1970–2A > G). Parental segregation by Sanger sequencing confirmed a heterozygous carrier state for the LAMA2 variant in both parents, thus confirming the diagnosis of autosomal recessive LAMA2-muscular dystrophy (LAMA2-MD) in the proband. The COL6A2 variant segregated with the as-yet asymptomatic mother. Musculoskeletal MRI of the proband at 12 months of age revealed peripheral involvement of the vastii, rectus femoris, gastrocnemius and the soleus, with relative central sparing, without areas of fatty infiltration; not serving to distinguish clearly between LAMA-MD and COL6A2- related disease. Reverse phenotyping of a 27-year-old mother revealed a normal musculoskeletal MRI and clinically absent red flags. Potential explanations for the heterozygous likely-pathogenic COL6A2 variant in the proband and the mother include (a) a coexisting diagnosis of autosomal dominant COL6A2-related myopathy, likely Bethlem myopathy, which has a variable clinical phenotype and age of onset; (b) a carrier state for autosomal recessive Ullrich congenital muscular dystrophy; or (c) a heterozygous COL6A2 variant contributing as a synergistic factor along with homozygous LAMA2 mutation. The couple was offered genetic counseling regarding the proband and the future pregnancies.

Keywords

next-generation sequencing - arthrogryposis - muscle disorders - genetic counseling - dual diagnosis

Publication History

Received: 27 January 2021

Accepted: 26 March 2021

Article published online:
19 June 2021

• References

• 1 Posey JE, Rosenfeld JA, James RA. et al. Molecular diagnostic experience of whole-exome sequencing in adult patients. Genet Med 2016; 18 (07) 678-685
• 2 Yang Y, Muzny DM, Xia F. et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014; 312 (18) 1870-1879
• 3 Chakravorty S, Nallamilli BRR, Khadilkar SV. et al. Clinical and genomic evaluation of 207 genetic myopathies in the Indian subcontinent. Front Neurol 2020; 11: 559327
• 4 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 5 Kopanos C, Tsiolkas V, Kouris A. et al. VarSome: the human genomic variant search engine. Bioinformatics 2019; 35 (11) 1978-1980
• 6 Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res 2019; 47 (D1): D886-D894
• 7 Geranmayeh F, Clement E, Feng LH. et al. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord 2010; 20 (04) 241-250
• 8 Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic Acids Res 2014; 42 (22) 13534-13544
• 9 Butterfield RJ. Congenital muscular dystrophy and congenital myopathy. Continuum (Minneap Minn) 2019; 25 (06) 1640-1661
• 10 Sframeli M, Sarkozy A, Bertoli M. et al. Congenital muscular dystrophies in the UK population: clinical and molecular spectrum of a large cohort diagnosed over a 12-year period. Neuromuscul Disord 2017; 27 (09) 793-803
• 11 Bushby KM, Collins J, Hicks D. Collagen type VI myopathies. Adv Exp Med Biol 2014; 802: 185-199
• 12 Lampe AK, Flanigan KM, Bushby KM. et al. Collagen type VI-related disorders. 2004 Jun 25 [Updated 2012 Aug 9]. In: Adam MP, Ardinger HH, Pagon RA. et al, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; ; 1993–2020. Accessed April 16, 2021 at: https://www.ncbi.nlm.nih.gov/books/NBK1503/
• 13 Oliveira J, Parente Freixo J, Santos M, Coelho T. LAMA2 Muscular Dystrophy. 2012 Jun 7 [updated 2020 Sep 17]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020 https://www.ncbi.nlm.nih.gov/books/NBK97333/ . Available at: Accessed April 16, 2021
• 14 Mercuri E, Lampe A, Allsop J. et al. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscul Disord 2005; 15 (04) 303-310
• 15 Liang Y, Li G, Chen S. et al. Muscle MRI findings in a one-year-old girl with merosin-deficient congenital muscular dystrophy type 1A due to LAMA2 mutation: a case report. Biomed Rep 2017; 7 (02) 193-196
• 16 Fan Y, Liu A, Wei C. et al. Genetic and clinical findings in a Chinese cohort of patients with collagen VI-related myopathies. Clin Genet 2018; 93 (06) 1159-1171
• 17 Tagliavini F, Pellegrini C, Sardone F. et al. Defective collagen VI α6 chain expression in the skeletal muscle of patients with collagen VI-related myopathies. Biochim Biophys Acta 2014; 1842 (09) 1604-1612
• 18 Marques Matos C, Alonso I, Leão M. Diagnostic yield of next-generation sequencing applied to neurological disorders. J Clin Neurosci 2019; 67: 14-18
• 19 Vona B, Maroofian R, Mendiratta G. et al. Dual diagnosis of Ellis-Van Creveld syndrome and hearing loss in a consanguineous family. Mol Syndromol 2017; 9 (01) 5-14